Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Rahul Bhargava: 2026 Haematology’s Shift From Chemotherapy to Immunotherapy
Nov 22, 2026, 12:37

Rahul Bhargava: 2026 Haematology’s Shift From Chemotherapy to Immunotherapy

Rahul Bhargava, Director and Head of Hematology, Hematoncology and Stem Cell Transplant at Fortis Health Care, shared a post on LinkedIn:

“2026: A Paradigm Shift in Haematology Care

We are witnessing one of the most exciting transformations in the history of haematology.

The era of conventional chemotherapy is gradually giving way to bispecific antibodies, CAR-T cells, and next-generation cellular therapies.

What began as treatment options for patients in the third or fourth line is now moving into second-line treatment and being explored in frontline clinical trials.

Even more exciting is the pace at which biotechnology companies are investing in new platforms, innovative molecules, and cellular engineering.

The future of haematology will not be defined by how much chemotherapy we deliver, but by how precisely we harness biology and the immune system to defeat disease.

2026 may well be remembered as a defining chapter in this transition.

From chemotherapy to immunotherapy. From treating disease to engineering better outcomes.

What an extraordinary time to be a haematologist!”

Rahul Bhargava: 2026 Haematology’s Shift From Chemotherapy to Immunotherapy

Find more posts featuring Rahul Bhargava on Hemostasis Today.